Raw data for the article: Successful Use of Heterologous CMV-Reactive T Lymphocyte to Treat Severe Refractory Cytomegalovirus (CMV) Infection in a Liver Transplanted Patient: Correlation of the Host Antiviral Immune Reconstitution with CMV Viral Load and CMV miRNome

Cytomegalovirus (CMV) infection is the most significant viral infection in hosts with compromised immune systems as solid organ transplant patients. Despite significant progress being made in the prevention of CMV disease in these patients, further therapeutic strategies for CMV disease and for the CMV reactivation prevention are needed. Here, we describe the outcome of the infusion of in vitro expanded CMV-reactive T-cells, taken from a healthy CMV-seropositive donor, in a liver-transplanted recipient with a refractory recurrent CMV. In this particular case, adoptive transfer of allogenic CMV-reactive T-lymphocytes resulted in the clearance of CMV infection and resolution of the pathological manifestations of the patient. In the study we also investigated circulating miRNAs, both cellular and viral, as potential biomarkers during the course of CMV infection. The results indicate that the infusion of allogenic CMV-reactive T-cells can be an effective strategy to treat CMV infection recurrence when the generation of autologous virus specific T cell clones is not possible.巨细胞病毒（Cytomegalovirus, CMV）感染是实体器官移植患者等免疫功能受损宿主中最具危害性的病毒感染性疾病。尽管目前在这类患者的CMV疾病预防领域已取得长足进展，但针对CMV疾病治疗及CMV激活预防的新型治疗策略仍有待开发。本研究针对1例罹患难治性复发性CMV感染的肝移植受者，详述了输注源自健康CMV血清学阳性供者的体外扩增CMV反应性T细胞的治疗结局。该病例中，同种异体CMV反应性T淋巴细胞的过继转移成功清除了患者体内的CMV感染，并使其病理表现完全缓解。本研究同时对CMV感染病程中的循环microRNA（miRNA，涵盖细胞源性与病毒源性两类）进行了检测分析，以探索其作为潜在生物标志物的价值。研究结果证实，当无法制备自体病毒特异性T细胞克隆时，输注同种异体CMV反应性T细胞可作为治疗CMV感染复发的有效方案。